Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adults
Open Access
- 16 December 2023
- Vol. 42 (2) , 295-309
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Nosocomial Co-Transmission of Avian Influenza A(H7N9) and A(H1N1)pdm09 Viruses between 2 Patients with Hematologic DisordersEmerging Infectious Diseases, 2016
- Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune ResponseJAMA, 2015
- Serological Responses to an Avian Influenza A/H7N9 Vaccine Mixed at the Point-of-Use With MF59 AdjuvantJAMA, 2014
- Epidemiology of Human Infections with Avian Influenza A(H7N9) Virus in ChinaNew England Journal of Medicine, 2014
- A Recombinant Viruslike Particle Influenza A (H7N9) VaccineNew England Journal of Medicine, 2013
- Probable person to person transmission of novel avian influenza A (H7N9) virus in Eastern China, 2013: epidemiological investigationBMJ, 2013
- H7N9 Influenza Viruses Are Transmissible in Ferrets by Respiratory DropletScience, 2013
- Pathogenesis and transmission of avian influenza A (H7N9) virus in ferrets and miceNature, 2013
- Human Infection with a Novel Avian-Origin Influenza A (H7N9) VirusNew England Journal of Medicine, 2013
- Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adultsVaccine, 2009